Home/Filings/4/0001140361-09-004824
4//SEC Filing

REGEN BIOLOGICS INC 4

Accession 0001140361-09-004824

CIK 0000883697operating

Filed

Feb 22, 7:00 PM ET

Accepted

Feb 23, 9:38 PM ET

Size

8.5 KB

Accession

0001140361-09-004824

Insider Transaction Report

Form 4
Period: 2009-02-18
MCNEIL ROBERT G
Director10% Owner
Transactions
  • Exercise/Conversion

    Common Stock

    2009-02-18$1.80/sh+62,500$112,50074,486 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2009-02-1862,5000 total
    Exercise: $1.80From: 2009-02-17Exp: 2017-10-18Common Stock (62,500 underlying)
Footnotes (2)
  • [F1]The original exercise price was $0.09 per share of common stock of ReGen Biologics, Inc. (the "Company"); however, after the Company effected a 1 for 20 reverse split of its common stock on November 29, 2008 (the "Reverse Split"), the exercise price became $1.80 per share of common stock.
  • [F2]The Company amended Mr. McNeil's Option Agreement dated October 18, 2007 on February 17, 2009 to allow for early exercise of the options issued pursuant to the Option Agreement. The Option Agreement provided for the issuance of 12,500 shares of Series E Preferred Stock of the Company upon exercise, or 62,500 shares of common stock immediately after mandatory conversion of the Series E Preferred Stock and after taking into account the Reverse Split. The Series E Preferred Stock manditorily converted upon effectiveness of the Reverse Split.

Documents

1 file

Issuer

REGEN BIOLOGICS INC

CIK 0000883697

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000883697

Filing Metadata

Form type
4
Filed
Feb 22, 7:00 PM ET
Accepted
Feb 23, 9:38 PM ET
Size
8.5 KB